Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
AUTHORS
Papakostas
GI ,
Fava
M ,
Baer
L ,
Swee
MB ,
Jaeger
A ,
Bobo
WV ,
Shelton
RC ,
. The American journal of psychiatry. 2015 6 18; (). appiajp201514101251
- PMID: 26085041 [PubMed].
ABSTRACT
The authors sought to test the efficacy of adjunctive ziprasidone in adults with nonpsychotic unipolar major depression experiencing persistent symptoms after 8 weeks of open-label treatment with escitalopram.
The authors sought to test the efficacy of adjunctive ziprasidone in adults with nonpsychotic unipolar major depression experiencing persistent symptoms after 8 weeks of open-label treatment with escitalopram.
Tags: Alumni Publications 2015